BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Helicos BioSciences Corporation (Jobs) Prices Initial Public Offering


5/24/2007 12:08:45 PM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (Nasdaq: HLCS) announced today that it has priced its initial public offering of 5,400,000 shares of common stock at $9.00 per share. All of the common stock is being offered by the company, and the common stock will trade on the NASDAQ Global Market under the symbol “HLCS.” The company has granted the underwriters an option to purchase up to an additional 810,000 shares to cover over-allotments, if any.

UBS Investment Bank is acting as the sole book-running manager for the offering. J.P. Morgan Securities Inc. is acting as a joint lead manager, with Leerink Swann & Company and Pacific Growth Equities, LLC acting as co-managers.

A registration statement was declared effective by the Securities and Exchange Commission on May 24, 2007. This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the final prospectus relating to the offering may be obtained from the prospectus department of UBS Investment Bank, Attn: Prospectus Department, 299 Park Avenue, New York, NY 10171 (212-821-3000).

About Helicos BioSciences

Helicos BioSciences Corporation is a life sciences company developing innovative genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The company has developed its proprietary True Single Molecule Sequencing technology to enable ultra-high-throughput genetic analysis based on the direct sequencing of single molecules of DNA or single DNA copies of RNA. The company’s corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800.

Contacts Helicos Biosciences Louise Mawhinney, 617-264-1870 Vice President and Chief Financial Officer



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES